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Abstract
Background and Objective Once-daily oral fingolimod is
approved in the EU as escalation treatment for adult
patients with highly active relapsing multiple sclerosis
(MS). The efficacy and safety profiles of fingolimod have
been well established in a large clinical development pro-
gramme and several papers reflecting the experience with
fingolimod in real-world settings have been published to
date. The GOLEMS study was designed to evaluate the
efficacy, safety and tolerability of fingolimod and the
impact of fingolimod treatment on disability progression
and work capability in patients with MS in routine clinical
practice in the Czech Republic.
Methods GOLEMS was a national, multicentre, non-in-
terventional, single-arm study conducted to analyse the
outcomes of a minimum of 12 months of fingolimod
therapy on primary and secondary endpoints. The primary
endpoint was to assess the proportion of relapse-free
patients and severity of MS relapses in patients treated with
fingolimod for 12 months. Secondary endpoints included
assessment of changes in disability progression evaluated
by the Expanded Disability Status Scale (EDSS) score and
work capability assessment measured through voluntary
completion of the WPAI-GH questionnaire. The predictive
factors for relapse-free status during fingolimod treatment
were also analysed.
Results Of the 240 enrolled patients, 219 completed the
12-month treatment period at the time of final analysis. In
the efficacy set (N = 237), the proportion of relapse-free
patients increased from 47 patients (19.6 %; 95 % confi-
dence interval [CI] 14.8–25.2) in the year before fin-
golimod initiation to 152 patients (64.1 %; 95 % CI
58.0–70.2) after 1 year of fingolimod treatment. Of the 85
patients who experienced at least one relapse after 1 year
of fingolimod treatment, 53 (62.4 %; 95 % CI 51.7–71.9)
reported only one relapse, while 25 (29.4 %; 95 % CI
20.8–39.8) and seven (8.2 %; 95 % CI 4.0–16.0) patients
had C2 relapses, respectively. No significant changes were
observed in EDSS scores over the 12-month treatment
period compared with baseline. The absolute number of
relapses during 2 years before initiation of fingolimod
treatment and baseline EDSS scores were identified as
significant independent predictors for ‘being relapse-free’
during the 12-month fingolimod treatment period. No trend
was established in work capability or number of missed
days at work due to the large proportion of missing data. Of
240 enrolled patients, 27 (11.3 %) patients discontinued
the study at or before the 12-month visit, 16 (6.7 %) dis-
continued because of adverse events related to study drug.
Only six (2.5 %) patients reported serious adverse events
related to the study drug.
Conclusion The results confirm the favourable safety and
efficacy profile of fingolimod under real-world conditions,
consistent with phase III trials.
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Key Points
Fingolimod is an approved oral therapy for patients
with multiple sclerosis (MS).
The GOLEMS study confirmed the efficacy of
fingolimod in patients with MS under real-world
settings.
These data support the safety and tolerability of
fingolimod in clinical practice.
1 Introduction
In the EU, once-daily oral fingolimod 0.5 mg (FTY720;
Gilenya, Novartis Pharma AG) is approved for the man-
agement of adult patients with highly active forms of
relapsing multiple sclerosis (MS), including those who fail
to respond to first-line disease-modifying therapy (DMT)
[1]. Fingolimod is a sphingosine-1-phosphate (S1P)
receptor modulator that prevents the egress of auto-reactive
lymphocytes from lymph nodes, thereby reducing their
infiltration into the central nervous system (CNS) [2, 3].
Phase III trials have shown superior efficacy of fingolimod
compared with intramuscular interferon (IFN)-b-1a (1-year
TRANSFORMS study) and placebo (2-year FREEDOMS
and FREEDOMS II studies) [4–6]. As of the second
quarter of 2016, approximately 155,000 patients have been
treated with fingolimod in both clinical trials and post-
marketing settings, and the total patient exposure is
approximately 343,000 patient-years [7].
Real-world studies complement the pivotal ‘random-
ized-controlled’ clinical trials conducted for approval
process in providing evidence on the safety and efficacy of
a drug under routine clinical practice [8]. The Gilenya
(FingOLimod) in prescribing conditions defined by the
CzEch regulator of drug reiMburSement (GOLEMS) study
was planned to provide the requested healthcare outcomes
data from MS patients receiving fingolimod under real-life
conditions to the Health Authority and General Health
Insurance Company of the Czech Republic.
In this report, we present the results from the GOLEMS
study, which investigated the effects of 12-month fin-
golimod treatment on the incidence and severity of relap-
ses, disability progression and work capability in patients
with MS.
2 Patients and Methods
2.1 Study Design and Patients
GOLEMS was a multicentre, observational, non-interven-
tional, single-arm study designed to assess treatment out-
comes in patients with MS receiving a minimum of
12 months of fingolimod therapy in the Czech Republic.
All existing MS centres in the Czech Republic were asked
to participate in the study. Fingolimod prescription was at
the discretion of the treating physician and patient and was
independent of participation in the study. Patients were
included in accordance with the locally approved pre-
scribing limitation by the Czech regulator for the reim-
bursement of drugs. Patients with MS who initiated
fingolimod treatment at study entry or within 6 months
before study entry as part of routine medical care were
included in the study. All patients were assessed and
monitored as per the revised label issued on 20 March 2012
and provided written informed consent form. Study visits
were performed at baseline (treatment initiation), month 1,
month 3 and every 3 months up to month 12, followed by
every 6 months until the end of the 36-month study period.
Women of child-bearing potential were informed about the
potential risk of fingolimod use to the fetus, about the need
for effective contraception and about the recommended
2-month wash-out period before a planned pregnancy.
2.2 Sample Size
A total of 240 patientswere enrolled over 2 years in this study.
Assuming a 5 % drop-out rate, it was expected that data from
228patientswith aminimumobservationperiodof12 months
would be available for statistical analysis at the end of the
study. This sample size was estimated to provide sufficient
precision for the frequency of patients without relapse (95 %
confidence interval [CI] 74–85; CI width 11 %).
2.3 Study Endpoints
The primary endpoints were the proportion of relapse-free
patients and severity of MS relapses in patients treated with
fingolimod for 12 months. The key secondary endpoints
were the incidence and severity of relapses after treatment
initiation at each post-baseline visit. In addition, changes in
the Expanded Disability Status Scale (EDSS) scores and
work capability (Work Productivity and Activity Impair-
ment-General Health [WPAI-GH] scores and number of
missed days at work) from baseline to 12 months were
assessed. Patients voluntarily completed the WPAI:GH
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questionnaire and answered a question about number of
missed days at work if they were employed. The safety
profile of fingolimod, including adverse events (AEs) and
serious AEs (SAEs), was also assessed. In addition to
primary efficacy results, the proportion of relapse-free
patients was assessed in the subgroup of patients treated
with natalizumab before initiating fingolimod treatment.
Medical health records collected during clinical practice
by the investigating physicians were used as the data
source in this study. Data were collected using the web-
based software OpenClinica, an electronic data capture
system compliant with the guidelines of Good Clinical
Practice (21 CFR Part 11). All investigators and study
personnel using OpenClinica were trained, and physicians
directly entered data into the system. Coherence checks
and correction of data were performed for validation of
data in the system.
2.4 Statistical Analysis
Three datasets were used for analysis: all-treated dataset,
efficacy dataset and completed set. The all-treated dataset
consisted of all enrolled patients with available data over
12 months after the start of Gilenya therapy and patients
who discontinued the study. The efficacy set consisted of
all treated patients with the exception of three patients for
whom the last visit recorded was at month 3 or sooner and
the reason for discontinuation was not due to treatment
failure or adverse events. The completed set consisted of
all patients who completed the 12-month observation per-
iod. With exception of the three patients (as described
above), the efficacy set included discontinued patients
which might cause overestimation of relapse-free patients
due to the fact that after discontinuation relapses were not
recorded. Analysis using the completed set might cause
underestimation of relapse-free patients due to the fact that
patients who might have discontinued due to lack of effi-
cacy (and relapses) were not in the completed set. Results
using the efficacy dataset were interpreted as primary
results. The completed set was used for sensitivity analysis
which showed very similar results to the efficacy set (as
described in Sect. 3); therefore, occurrence of potential
selective bias was excluded.
Data were analysed descriptively including 95 % CIs.
Wald asymptotic CIs were calculated to determine the
percentage of relapse-free patients, while the frequency and
severity of relapses were evaluated using Wilson CIs,
which are appropriate when percentages are close to 0 or
100.
The EDSS score was recorded at every visit: Baseline,
month 1 (M1), month 3 (M3), month 6 (M6) and month 12
(M12), and an additional EDSS score was performed dur-
ing relapses to evaluate the severity of relapse. As the study
was non-interventional, visit scheduled was not strictly
completed. MS relapse was defined as appearance of a new
neurological abnormality or worsening of previously
stable or improving pre-existing neurological abnormality,
separated by at least 30 days from onset of a preceding
clinical demyelinating event [9]. The relapse severity was
graded as: mild (EDSS increase by 0.5 point, or 1-point
change in one to three functional system (FS) scores),
moderate (EDSS increase by 1 or 2 points, or 2-point FS
change in one or two systems, or 1-point change in four or
more systems), or severe (exceeding moderate criteria)
[10].
Multivariate logistic regression was used to identify
baseline characteristics, which are strongly predictive of
being relapse-free during 12 months of fingolimod therapy.
The following baseline characteristics were included into
the multivariate logistic regression: age, duration of diag-
nosis, number of relapses during the previous year, severity
of last relapse (mild/moderate/severe), previous MS ther-
apy (any interferon or glatiramer acetate/natalizumab in the
period at least 3 months before beginning therapy with
fingolimod/other medication), EDSS score at baseline (B3
vs.[3) and number of relapses during the last 2 years (0–2
vs. C3). The level of significance was set to 5 %; therefore,
characteristics not associated with the probability of being
relapse-free after 12 months of treatment were excluded,
and only significant independent predictors were retained
in the final model. In addition, the effect of EDSS scores on
the proportion of relapse-free patients was presented using
Kaplan–Meier (KM) curves. KM curves for EDSS score at
baseline of B3 versus[3 were compared using log-rank
test. Within-patient changes from baseline in EDSS score
were calculated and analysed only descriptively because
the results of descriptive analysis showed no change to be
tested. Data were statistically analysed using SAS software
version 9.4 (SAS, Cary, NC, USA).
3 Results
A total of 240 patients were enrolled, and all were included
in the all-treated set for final analysis. At the end of
12 months or earlier 27 (11.3 %) patients discontinued the
study. The efficacy dataset had a total of 237 patients.
Three patients’ with data available only up to the 3-month
visit and reason for discontinuation not related to safety or
efficacy issues were excluded from the efficacy analysis,
since absence of relapse might have been due to the short
observation period. A total of 219 patients completed the
12-month treatment period and were included in the com-
pleted data set. The distribution of patients in the all-trea-
ted, efficacy and completed sets at the time of final analysis
is presented in Fig. 1.
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3.1 Demographics and Baseline Characteristics
Table 1 presents the demographics and baseline character-
istics of all enrolled patients (N = 240). Patients were pre-
dominantly females (70.4 %), with an average age of
37.4 years. At baseline, the mean time since the first MS
symptom before study entry was 10.4 years, and the mean
EDSS score was 3.4. Based on available data from 23
patients at baseline, the mean number of missed days at work
within 3 months before study entry was 8.3. Of 240 enrolled
patients, 47 (19.6 %) did not experience any relapse, 54
(22.5 %) reported one relapse, 102 (42.5 %) reported two
relapses and 37 (15.4 %) experienced[2 relapses within
1 year prior to fingolimod initiation. All analysed patients
had received previous treatment with any DMT before
receiving fingolimod. Fifty-nine patients out of 240 included
were treated with natalizumab before initiating fingolimod
(Table 2). All patients switched directly fromnatalizumab to
fingolimod. There were 29 (49 %) patients who were
relapse-free in the year prior to initiation of fingolimod
treatment. The mean duration of the wash-out period after
natalizumab termination was 105.8 days, median 87 days.
3.2 Effect of Fingolimod Treatment on MS Relapse
Status
3.2.1 Efficacy Set
Among 237 patients, 152 (64.1 %; 95 % CI 58.0–70.2;
Fig. 2a) did not report any relapse as compared to the
previous year with only 47 patients (19.6 %; 95 % CI
14.8–25.2) reporting to be relapse-free. Of the 24 discon-
tinued patients, ten were relapse-free and had received
treatment for an average of 145.9 (range 14–305) days.
3.2.2 Completed Set
Out of 219 patients, 142 (64.8 %; 95 %CI 58.5–71.2) did not
have any relapse over 12 months of fingolimod treatment.
All the results presented below are based on the efficacy
set.
3.3 Effects of Fingolimod Treatment on Frequency
and Severity of Relapse
Fingolimod reduced the average number of relapses per
patient (0.61, 95 % CI 0.48–0.73) after 12 months of ther-
apy compared with the mean number of relapses per patient
(1.56; 95 % CI 1.43–1.69) 12 months prior to the study
entry, which represents a reduction of 0.96 (95 % CI
0.80–1.11) relapses, and relative reduction of 65.4 % (95 %
CI 57.7–73.0). Of the 85 patients with relapses, 25 (29.4 %)
and seven (8.2 %) reported C2 relapses, respectively, during
the 12-month treatment, compared with 102 (42.5 %) and 37
(15.4 %) patients in the year before fingolimod treatment
(Fig. 2a). Out of the total 125 relapses reported within
12 months of fingolimod treatment, the proportions of mild,
moderate and severe relapses were 46.4 % (95 % CI
37.9–55.1), 44.8 % (95 % CI 36.4–53.5) and 8.8 % (95 %
CI 5.0–15.1), respectively (Fig. 2b). The mean EDSS score
performed during relapse was 4.36 (95 % CI 4.11–4.61).
3.4 Independent Predictors for Being Relapse-Free
Logistic regression analysis showed that baseline EDSS
scores and number of relapses within 2 years before fin-
golimod initiation were significant and independent pre-
dictors for being relapse-free during the 12-month
fingolimod treatment period. Analysis using the completed
set showed that patients with baseline EDSS score B3 had
higher odds (odds ratio [OR] = 2.28, 95 % CI 1.23–4.07,
p = 0.005) of not relapsing during 12 months of fin-
golimod therapy compared with patients for whom the
baseline EDSS score was[3. Patients with B2 relapses
during previous 2 years had higher odds of not relapsing on
fingolimod therapy (OR = 3.27, 95 % CI 1.85–5.878,
p\ 0.0001) compared with patients who had[2 relapses.
Fig. 1 Allocation of subjects in
different data sets analysed in
the GOLEMS study. AEs
adverse events
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3.5 Kaplan–Meier (KM) Analysis of Relapse-Free
Patients and Time to First Relapse
EDSS score at baseline was significantly associated with
the proportion of relapse-free patients. Further exploration
using KM estimates showed that the proportion of relapse-
free patients was higher (68.1 %) in the subgroup of
patients with a baseline EDSS score B3 compared with
those with an EDSS score[3 at baseline (50.9 %; log-rank
test p = 0.0060; Fig. 3).





Age (years) 37.4 ± 9.3
Time since the first MS symptom before study entry (years) 10.35 ± 6.7
Relapse-free patients within 1 year before fingolimod initiation 47 (19.6)
Relapse-free patients on natalizumab before fingolimod within 1 year before fingolimod initiation 29 (49.2)
Frequency of relapses within 1 year before fingolimod initiation
Patients with 1 relapse 54 (22.5)
Patients with C2 relapses 139 (57.9)
Relapse-free patients within 2 years before fingolimod treatment 35 (14.6)
Frequency of relapses within 2 years before fingolimod initiation
Patients with 1 relapse 27 (11.3)
Patients with C2 relapses 178 (73.2)
EDSS score for last 3 months before study entry or at the initiation of fingolimod treatment 3.4 ± 1.3
Number of missed days at work during 3 months before study entrya 8.3 ± 20.0
Previous DMT treatment
Copaxone n, (%) 67 (27.9)
Duration of treatment (mo) 46.5 ± 38.9
Tysabri (Natalizumab) n, (%) 59 (24.6)
Duration of treatment (mo) 26.7 ± 14.9
Rebif 44 lg (Interferon beta-1a) n, (%) 46 (19.2)
Duration of treatment (mo) 34.3 ± 38.2
Rebif 22 lg (Interferon beta-1a) n, (%) 29 (12.1)
Duration of treatment (mo) 36.1 ± 39.4
Avonex (Interferon beta-1a) n, (%) 27 (11.3)
Duration of treatment (mo) 42.3 ± 41.4
Betaferon (Recombinant interferon beta-1b) n, (%) 22 (9.2)
Duration of treatment (mo) 57.7 ± 35.2
Otherb n, (%) 12 (5.0)
Duration of treatment (mo) 82.8 ± 56.9
Azathioprine n, (%) 6 (2.5)
Duration of treatment (mo) 101.8 ± 57.2
Extavia n, (%) 7 (2.9)
Duration of treatment (mo) 19.7 ± 14.6
IVIG n, (%) 4 (1.7)
Duration of treatment (mo) 43.8 ± 41.5
Values are expressed as mean ± SD or n (%)
CI confidence interval, DMT disease modifying therapy, EDSS Expanded Disability Status Scale, GOLEMS Gilenya (FingOLimod) in pre-
scribing conditions defined by the CzEch regulator of drug reimbursement, MS multiple sclerosis, SD standard deviation
a n = 23
b Other medication: Teriflunomide, Prednisone, Cladribine, Dimethyl fumarate, Ocrelizumab, Methylprednisolone
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3.6 Changes in Disability Progression and Work
Capability Assessment
Disability progression, as assessed by EDSS scores,
remained constant over the observation period. EDSS score
was 3.4 ± 1.3 at baseline and 3.4 ± 1.4 at 12 months
(Tables 1, 3). Within-patient differences between the
baseline value and EDSS score at 12 months was
0.05 ± 0.56 (95 % CI -0.02 to 0.13), the median value of
the change was 0. For analysis of change in work capability
assessment, data were available at baseline from 23
patients, and even fewer responses were available for the
treatment period. Descriptive analysis of data did not
indicate any trends in change from baseline. Mean values
of within-patient changes in EDSS score from baseline
ranged from -0.01 to 0.05 at individual post-baseline visits
(95 % CI of means included 0 at all post-baseline visits),
median values of the change were 0 at all post-baseline
visits. Since the response rate was approximately 10 % and
a large set of data was missing, no detailed analysis in
terms of trends of changes in these parameters was
performed.
3.7 Relapse Status in Patients Receiving
Natalizumab before Fingolimod Initiation
Of the 59 patients who had received natalizumab before
fingolimod, 31 (52.5 %) were without relapse within the
first 12 months on fingolimod compared with 29 (49.2 %)
relapse-free patients in the last year prior to fingolimod
initiation. Out of 28 patients with relapses after 1 year of
treatment with fingolimod, 12 (42.9 %) had mild relapses,
while ten (35.7 %) and six (21.4 %) had moderate and
severe relapses, respectively (Fig. 4).
Table 2 Demographics and
baseline characteristics of
patients treated with






Age (years) 37.7 ± 9.7
Time since the first MS symptom before study entry (years) 12.3 ± 6.4
Relapse-free patients within 1 year before fingolimod initiation 29 (49.2)
Frequency of relapses within 1 year before fingolimod initiation
Patients with 1 relapse 16 (27.1)
Patients with C2 relapses 14 (23.7)
Relapse-free patients within 2 years before fingolimod treatment 22 (37.3)
Frequency of relapses within 2 years before fingolimod initiation
Patients with 1 relapse 13 (22.0)
Patients with C2 relapses 24 (40.7)
EDSS score for last 3 months before study entry or at the initiation of fingolimod treatment 3.5 ± 1.3
Number of missed days at work during 3 months before study entrya 23.3 ± 36.2
Values are expressed as mean ± SD or n (%)
CI confidence interval, EDSS Expanded Disability Status Scale, GOLEMS Gilenya (FingOLimod) in
prescribing conditions defined by the CzEch regulator of drug reimbursement, MS multiple sclerosis, SD
standard deviation
a n = 6
Fig. 2 a Effect of 12 month
fingolimod treatment on
frequency of relapses
(N = 237). b Severity of
relapses (n = 125a). aTotal
number of relapses reported in
85 patients of efficacy set
(N = 237)
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3.8 Adverse Events and Serious Adverse Events
Of the 240 patients included in the analysis, 84 (35.0 %)
reported 109 AEs, ten (4.2 %) reported 11 SAEs and six
(2.5 %) reported SAEs related to the study drug. In 53
(22.1 %) patients, AEs were judged as related to the
study drug. No deaths were reported during the study
(Tables 4, 5). Liver function test results were abnormal
in 4.6 % of patients at baseline. During the patient visit
from M1 to M12, abnormal liver function test results
were reported in 15.3–29.4 % of patients (Table 6).
Liver function abnormality was asymptomatic and led to
discontinuation of fingolimod only in four patients. The
mean lymphocyte counts were 0.571–0.654 9 109/L
over the course of the 12-month fingolimod treatment
period. Sixteen patients (6.7 %) discontinued the treat-
ment due to the following AEs: macular oedema
(n = 3), lymphopenia (n = 3), liver transaminase ele-
vation (n = 2), hepatopathy (n = 2), pain (n = 2) and
gynaecological infection (n = 4). First-dose cardiac
Fig. 3 Proportion of relapse free patients in the efficacy set
(N = 237) by baseline EDSS score (Kaplan–Meier analysis).
Kaplan–Meier plot depicts the proportion of relapse-free patients in
the subgroups of patients with a baseline EDSS score B3 compared
with an EDSS score[3 at baseline. EDSS Expanded Disability Status
Scale




(N = 175) [19]
Academic center
in Middle East
(N = 122) [23]
Portuguese real-
world population




Female 169 (70.4) 132 (75.4) 77 (63.1) 64 (61.54) 2.884 (71.9)
Male 71 (29.6) 43 (24.6) 45 (36.9) 36 (38.4) 1.126 (28.1)
Mean age (years) 37.4 ± 9.3 33.3 ± 9.2 35.3 ± 9.9 39.0 ± 9.35 39.1 ± 10.0
Mean disease duration (years) 10.35 ± 6.7 7.2 ± 5.2 7.4 ± 6.6 10.29 ± 7.27 8.2 ± 6.3
Mean duration on fingolimod (mo) 10.77 ± 2.2 21.7±9.1 19.18±11.0 21.37 ± 10.57 879.2 ± 516.4 days
Pre-treatment patient characteristics
Relapse-free patients 47 (19.6%) 57 (32.6 %) 21 % –
ARR – – 1.16 1.04 1.5
EDSS score 3.4±1.3 2.60 ± 1.44 2.3 ± 1.5 2.5 3.0±1.7
MRI activity – 136 (77.7%) –
Post-treatment patient characteristics
Relapse-free patients 152 (64.1 %) 151 (86.3 %)a 77.3 %c – 68.5–75.5 %
ARR – – 0.29c 0.5a 0.43a
EDSS score 3.4±1.4 2.26 ± 1.49b 1.9 ± 1.7d 2.0e 2.89–2.91
MRI activity – 32 (18.3 %)a – –
Safety
Adverse events 84 (35.0 %) 43 (24.6 %) 76 (62.3 %) 59 (56.7 %)
Discontinuation/withdrawal 16 (6.7 %) 20 (11.4 %) 2 (1.6 %) 10.6 %
ARR Annualized Relapse Rate, EDSS Expanded Disability Status Scale, MRI magnetic resonance imaging, PANGAEA Post-Authorization Non-
interventional German sAfety study of GilEnyA in RRMS patients
a p\ 0.001
b p = 0.031
c p\ 0.0001
d p = 0.001
e p = 0.145
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monitoring was prolonged in four patients due to tran-
sitional non-clinically significant electrocardiogram
(ECG) atypia (n = 1), atrioventricular (AV) block first
degree (n = 1) and just for prevention of any cardio-
vascular effect (n = 2). One patient reported pregnancy
after 483 days of initiating fingolimod and subsequently
terminated the treatment.
4 Discussion
The primary objective of the present study was to evaluate
the incidence and severity of MS relapses in patients
treated with fingolimod. In this study a majority of patients
treated with fingolimod remained relapse-free (64.1 %);
the proportion of relapse-free patients was lower than that
observed in the phase III FREEDOMS study (70.4 %) and
TRANSFORMS study (82.6 %) and phase II (75–77 %)
trials [4, 5, 11]. In both the phase II and phase III studies
the populations of patients had shorter disease duration and
lower baseline EDSS than patients in the GOLEMS study.
Moreover, in both the FREEDOMS and TRANSFORMS
studies only the confirmed relapses were taken into
account. The proportion of relapse-free patients after
12 months of fingolimod treatment in our study is similar
to the proportion of relapse-free patients in the large post-
marketing PANGAEA study (63.2 %) [12]. However, the
proportion of relapse-free patients was high enough to
demonstrate a clinical benefit for patients with MS. The
efficacy set included discontinued patients, which might
cause overestimation of relapse-free patients due to the fact
that after discontinuation relapses were not recorded. On
the other hand, analysis using the completed set might
cause underestimation of relapse-free patients due to the
fact that patients who might have discontinued due to lack
of efficacy (and relapses) were not included in the
Fig. 4 a Effect of 12-month fingolimod treatment among patients
treated with natalizumab before study start (N = 59). b Severity of
relapses (n = 28a). aTotal number of relapses reported in patients
treated with natalizumab before fingolimod. Natalizumab was
administered within 1 year before fingolimod treatment start




N (%) of patients
(N = 240)
Any AEs 109 84 (35.0)
SAEs 11 10 (4.2)
AEs related to study drug 62 53 (22.1)
Action taken
No action required 38 34 (14.2)
Other concomitant medication prescribed 37 29 (12.1)
Study treatment permanently discontinued 13 13 (5.4)
Study treatment adjusted/temporarily interrupted 10 9 (3.8)
Study treatment permanently discontinued and other concomitant
medication prescribed
4 4 (1.7)
Non-medicamentous therapy given 4 3 (1.3)
Study treatment adjusted/temporarily interrupted and other concomitant
medication prescribed
2 2 (0.8)
Study treatment adjusted/temporarily interrupted, non-medicamentous
therapy given and other concomitant medication prescribed
1 1 (0.4)
Outcome
Resolved 72 57 (23.8)
No change in condition 22 22 (9.2)
Improvement of condition 13 12 (5.0)
Resolved with sequelae 1 1 (0.4)
Worsening of condition 1 1 (0.4)
AE adverse events, SAEs serious adverse events
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completed set. The completed set was used for sensitivity
analysis, which showed very similar results to the efficacy
set (as described in the Results section); therefore, occur-
rence of potential selective bias was excluded. In the effi-
cacy set (N = 237), treatment with fingolimod led to a
reduction in the mean number of relapses per patient per
year from 1.6 at baseline to 0.61 at 12 months (reduction of
65.4 %), indicating favourable disease control.
In the present study, the proportion of relapse-free
patients constantly decreased over time (approximately
91 % [M1] to 64 % [M12]). No trend could be established
based on severity of relapses. Thus, it is challenging to
draw a conclusion regarding the association between
treatment and severity of relapses. Treatment with fin-
golimod was associated with stable EDSS scores over the
12-month observation period.
Results also suggest that patient with lower baseline
EDSS scores are more likely to be relapse-free during
fingolimod therapy, implying that early initiation of fin-
golimod treatment is for better relapse control. Further-
more, the number of relapses within 2 years prior to
fingolimod initiation was also an independent predictor for
being relapse-free. These results are consistent with the
previous findings, which demonstrated that a better clinical
outcome was most influenced by immunomodulatory
treatment and lower EDSS score change during the relapse
[13, 14]. Of note, Hoepner et al. identified an EDSS
score[3 as a predictive factor for relapse; however, these
observations were based on a different patient population
comprising patients switching from natalizumab to fin-
golimod [15]. A subgroup investigation of the FREE-
DOMS trial also showed a consistent, significant effect of
fingolimod versus placebo on ARR in patients who had
relapse activity despite receiving interferon beta during the
year before study enrolment and patients with an EDSS
over 3.5 [16].
In the subgroup of patients treated with natalizumab
(N = 59) before fingolimod the number of patients without
relapses in the year prior to fingolimod initiation was not
surprisingly higher (49.2 %) compared with the overall
cohort (19.6 %). After 1 year of fingolimod treatment the
number of patients keeping this beneficial treatment effect
(i.e. remained stable without relapse) was even slightly
increased (52.5 %). In the subgroup of patients switching
from natalizumab to fingolimod a numerically higher per-
centage of patients (21.4 %) with severe relapses was noted
compared with the overall analysis (12.9 %), probably
owing to an overall lower patient number in this subgroup.
Our results conflict with a recent report in which fin-
golimod showed lesser efficacy in patients switching from
natalizumab and a higher proportion of patients showed
clinical (41 %) or MRI activity (54 %) [17].
Treatment with fingolimod was well tolerated and no
new safety issues emerged. The discontinuation rate at
12 months was lower (11.3 %) than that observed in phase
III clinical trials (FREEDOMS discontinuation rate:
18.8 %; TRANSFORMS discontinuation rate: 12.4 %) and
was mainly because of AEs (59.3 %) [4, 5].
The results of our study are similar to the 24-month
interim results of the PANGAEA (Post-Authorization Non-
interventional German sAfety study of GilEnyA in RRMS
patients) study (n = 2239) conducted in Germany. The
PANGAEA study investigated the safety, efficacy and
pharmacoeconomic data from fingolimod-treated patients
over 5 years [12, 18]. In PANGAEA,[63 % of patients
were free from relapses during years 1 and 2, comparable
to 64.1 % of relapse-free patients at 12 months in the
GOLEMS study. After 12 months of fingolimod treatment,
both studies showed a similar average number of relapses
per patient-year (GOLEMS: 0.61, N = 237; PANGAEA:
0.42, N = 2229) and similar relapse reduction (GOLEMS:
67 %; PANGAEA: 72 %). Moreover, the safety profile of
fingolimod was similar in both studies: 4.7 and 6.0 % of
patients discontinued due to AEs in the PANGAEA and
GOLEMS studies, respectively. No new safety signals
were detected. An indirect comparison of studies con-
ducted under real-world and clinical trial settings demon-
strated similar results (Table 3) [4, 12, 18–22]. Treatment
non-response is frequent and first-line therapies may not
adequately control MS. Early switch to therapies with
higher efficacy, such as fingolimod, may improve long-
term outcomes and reduce irreversible damage, which
correlates with the number of relapses and disability
progression.
This non-interventional design of the study provides
relevant information on the safety, efficacy and tolerability
of drugs that may help in the treatment of patients with MS
under real-world settings. One of the limitations was the
Table 6 Liver function test results by visit
Variable Baseline M1 M3 M6 M9 M12
No. of pts. tested 239 215 229 220 153 195
Abnormal results, N (%) 11 (4.6 %) 33 (15.3 %) 54 (23.6 %) 59 (26.8 %) 45 (29.4 %) 51 (26.2 %)
Values above 39 ULN, N (%) 0 6 (2.8 %) 15 (6.6 %) 17 (7.7 %) 11 (7.2 %) 16 (8.2 %)
M month, ULN upper limit of normal
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large amount of missing data for the assessment of changes
in work capability due to the low response rate (*10 %) in
completing the WPAI-GH questionnaires, which prevented
any meaningful statistical interpretation. In this study,
patients were observed only for 12 months; hence, results
should be interpreted with caution in the absence of long-
term follow-up.
5 Conclusion
In conclusion, the results of this 12-month GOLEMS study
confirmed the favourable efficacy and safety profile of
fingolimod, as evidenced by reductions in the frequency
and severity of relapses and the low incidence of AEs
under real-world conditions in the Czech Republic.
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